서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 4 of 4

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2021-08	Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival Slamon, D. J.; Neven, P.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.; Petrakova, K.; Bianchi, G. Valeria; Martin, M.; Nusch, A.; Sonke, G. S.; De la Cruz-Merino, L.; Beck, J. T.; Ji, Y.; Wang, C.; Deore, U.; Chakravartty, A.; Zarate, J. P.; Taran, T.; Fasching, P. A. Annals of Oncology, Vol.32 No.8, pp.1015-1024	DOI
2021-10	Corrigendum to Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353) Slamon, D.J.; Neven, P.; Chia, S.; Jerusalem, G.; De, Laurentiis M.; Im, S.; Petrakova, K.; Valeria, Bianchi G.; Martin, M.; Nusch, A.; Sonke, G.S.; De, la Cruz-Merino L.; Beck, J.T.; Ji, Y.; Wang, C.; Deore, U.; Chakravartty, A.; Zarate, J.P.; Taran, T.; Fasching, P.A. Annals of Oncology, Vol.32 No.10, pp.1307-1307	DOI
2023-08	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant Neven, P.; Fasching, P.A.; Chia, S.; Jerusalem, G.; De, Laurentiis M.; Im, S.-A.; Petrakova, K.; Bianchi, G.V.; Martin, M.; Nusch, A.; Sonke, G.S.; De, la Cruz-Merino L.; Beck, J.T.; Zarate, J.P.; Wang, Y.; Chakravartty, A.; Wang, C.; Slamon, D.J. Breast Cancer Research, Vol.25 No.1, p. 103	DOI
2023-08	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant Neven, P.; Fasching, P. A.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.-A.; Petrakova, K.; Bianchi, G. V.; Martín, M.; Nusch, A.; Sonke, G. S.; De la Cruz-Merino, L.; Beck, J. T.; Zarate, J. P.; Wang, Y.; Chakravartty, A.; Wang, C.; Slamon, D. J. Breast Cancer Research, Vol.25(1):103	view file DOI

1